Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Asset Writedowns and Impairment: 2010-2013

Historic Asset Writedowns and Impairment for Cytokinetics (CYTK) over the last 3 years, with Sep 2013 value amounting to $103,000.

  • Cytokinetics' Asset Writedowns and Impairment changed negligibly% to $103,000 in Q3 2013 from the same period last year, while for Sep 2013 it was $412,000, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $2.8 million for FY2021, which is N/A change from last year.
  • Latest data reveals that Cytokinetics reported Asset Writedowns and Impairment of $103,000 as of Q3 2013, which was down 0.00% from $103,000 recorded in Q2 2013.
  • Cytokinetics' 5-year Asset Writedowns and Impairment high stood at $164,941 for Q1 2011, and its period low was -$162,564 during Q4 2010.
  • Over the past 3 years, Cytokinetics' median Asset Writedowns and Impairment value was $103,000 (recorded in 2013), while the average stood at $108,631.
  • Per our database at Business Quant, Cytokinetics' Asset Writedowns and Impairment skyrocketed by 163.36% in 2011 and then tumbled by 37.55% in 2012.
  • Quarterly analysis of 4 years shows Cytokinetics' Asset Writedowns and Impairment stood at -$162,564 in 2010, then soared by 163.36% to $103,000 in 2011, then remained steady at $103,000 in 2012, then remained steady at $103,000 in 2013.
  • Its Asset Writedowns and Impairment stands at $103,000 for Q3 2013, versus $103,000 for Q2 2013 and $103,000 for Q1 2013.